German chemicals company BAYER has concluded an alliance with the US biotechnologies company, AVIGEN, in gene therapy for the treatment of haemophilia type B. The contact is worth a total of $60 million. It includes, in particular, the acquisition of AVIGEN shares by BAYER. According to The Wall Street Journal Europe, BAYER will hold 2.5% of the capital of its partner after the transaction.